Strategic Drug Development & Commercialization Advisory

Core Value Proposition

A Commercial Lens Across the Development Continuum

Bringing a rare disease therapy to market requires far more than promising science. It requires a sequence of high-quality strategic decisions across development, regulatory planning, clinical execution, stakeholder engagement, financing, partnering, and commercialization. The timing and quality of those decisions can materially influence not only the probability of approval, but also the value of an asset to patients, partners, investors, and shareholders.

I advise biotechnology and pharmaceutical companies on the strategic development and commercialization of rare disease assets. My role is to help leadership teams assess where an asset stands today, identify the issues most likely to affect future value, and focus resources on the actions and relationships that can have the greatest impact on long-term success.

The advisory approach is intentionally cross-functional. It connects the scientific and clinical realities of a program with the commercial questions that eventually determine whether a therapy can achieve meaningful adoption:

• Is the right indication being prioritized?
• Are the clinical endpoints and evidence likely to support a compelling value proposition?
• Are the right centers and investigators involved?
• Is the development path aligned with the markets that matter most?
• Is the company building the relationships and evidence needed for licensing, investment, acquisition, or launch?

This perspective can be especially valuable for emerging companies, where capital is limited and a small number of decisions can have outsized consequences. Early identification of a flawed assumption, an underdeveloped clinical relationship, a weak product-priority decision, or a poorly sequenced commercialization plan can prevent costly delays and preserve strategic flexibility.

The Objective